Key Summary
- The strategic partnership between Reset Health and Pharmacy2U aims to increase the focus on weight loss programmes.
- Patients will receive support on their weight-loss journey via Reset Health’s clinical team on its digital health platform.
- This includes monthly consultations, evidence-based coaching and nutrition support, with access to health coaches, dietitians, and ongoing psychological support.
Leading online pharmacy Pharmacy2U has entered into a strategic partnership with Reset Health, the provider of personalised management for chronic diseases, to help improve patient outcomes with GLP-1 medications for weight loss.
The collaboration will launch in the first quarter of 2026, with Pharmacy2U patients receiving Reset Health’s digitally delivered wraparound care to achieve sustained results.
Every patient receiving treatment will be able to access medication online, with one-click repeat prescription, and be directed to expert clinical support.
Participants will receive support on their weight-loss journey via Reset Health’s clinical team on its digital health platform, which includes monthly consultations, evidence-based coaching and nutrition support, with access to health coaches, dietitians, and ongoing psychological support.
The strategic partnership between Reset Health and Pharmacy2U aims to increase the focus on weight loss programmes.
The data will be continuously gathered, and evaluations will add to a growing body of clinical evidence demonstrating that taking a holistic approach to weight management delivers long-lasting outcomes for patients.
Recent studies by various institutions, including Oxford's Nuffield Department of Primary Care Health Sciences, have shown that patients coming off GLP-1 medications regain weight more rapidly than after dietary interventions. In many cases, they even exceed their original weight.
This calls for the need to ensure eligible patients are appropriately retained on GLP-1 medications in the long term, with clinical oversight, to ensure they receive wider health benefits and prevent weight fluctuations.
Medication licensing also demands that GLP-1 medication for obesity must be delivered alongside dietary, psychological and behavioural support, whilst increasing physical activity, for the best long-term outcomes.
Reset Health CEO Oliver McGuinness said, “GLP-1s can transform the health of the nation, but we founded Reset Health because we knew treating chronic conditions requires more than medication alone. It needs continuous clinical support that is tailored to the needs of patients.
"This strategic partnership with Pharmacy2U is the foundation of how together we will transform obesity treatment in the UK. By combining rapid GLP-1 access with expert clinical wraparound care, we can help patients achieve sustained health benefits and behaviour change that meaningfully enable them in their everyday life.”
Pharmacy2U CEO Kevin Heath said, “Together with Reset Health, we’re excited to be pioneering a new digitally-driven approach to medicated weight loss that aims to put control back in the hands of patients.”
McGuinness added, “The sales of obesity medicines are rapidly changing with the advent of new policies in how treatments are getting to patients under the US administration.
"This model has the potential to streamline the delivery of medication, and if successful, with cost and efficiency pressures on healthcare systems around the world, this could be replicated in other international medication dispensation markets.”
